<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04658199</url>
  </required_header>
  <id_info>
    <org_study_id>PSP002</org_study_id>
    <secondary_id>2019-001127-12</secondary_id>
    <nct_id>NCT04658199</nct_id>
  </id_info>
  <brief_title>A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy</brief_title>
  <official_title>An Open-Label Extension Study to Evaluate the Safety and Tolerability of Long-Term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Biopharma SRL</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the long-term safety and tolerability of UCB0107 in&#xD;
      study participants with progressive supranuclear palsy (PSP).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">November 16, 2020</start_date>
  <completion_date type="Anticipated">November 2026</completion_date>
  <primary_completion_date type="Anticipated">November 2026</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment emergent adverse events from Baseline of the open-label extension to the end of the study</measure>
    <time_frame>From Baseline of the open-label extension to end of study visit (Month 60)</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory finding) in study participants, users, or other persons, whether or not related to the investigational medicinal product (IMP).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Progressive Supranuclear Palsy</condition>
  <arm_group>
    <arm_group_label>UCB0107 (bepranemab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this study arm will receive Intravenous UCB0107.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UCB0107 (bepranemab)</intervention_name>
    <description>UCB0107 (bepranemab) will be administered in a predefined dosage. Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous</description>
    <arm_group_label>UCB0107 (bepranemab)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant meets the criteria for possible or probable progressive supranuclear palsy&#xD;
             (PSP) Richardson's Syndrome according to the Movement Disorder Society-PSP criteria&#xD;
             (Hoeglinger et al, 2017)&#xD;
&#xD;
          -  Participant completed the Treatment Period (regardless of the total number of&#xD;
             infusions) in PSP003 (NCT04185415)&#xD;
&#xD;
          -  Participant can be male or female&#xD;
&#xD;
             a) A male participant must agree to use contraception as detailed in the protocol&#xD;
             during the Treatment Period and for at least 6 months after the last dose of study&#xD;
             treatment and refrain from donating sperm during this period b) A female participant&#xD;
             is eligible to participate if she is not pregnant, not breastfeeding, and at least one&#xD;
             of the following conditions applies: I. Not a woman of childbearing potential (WOCBP)&#xD;
             OR II. A WOCBP who agrees to follow the contraceptive guidance in the protocol during&#xD;
             the Treatment Period and for at least 6 months after the last dose of study treatment.&#xD;
&#xD;
          -  Participant (or legal representative, as applicable and acceptable by local&#xD;
             regulations) is capable of giving signed informed consent, which includes compliance&#xD;
             with the requirements and restrictions listed in the ICF and in this protocol.&#xD;
             Informed consent must be obtained before initiating any study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant has met a mandatory withdrawal and/or stopping criterion in PSP003&#xD;
             (NCT04185415)&#xD;
&#xD;
          -  Participant made a suicide attempt (including an actual attempt, interrupted attempt,&#xD;
             or aborted attempt) during PSP003 (NCT04185415), or has current suicidal ideation with&#xD;
             at least some intent to act as indicated by a positive response (&quot;Yes&quot;) to either&#xD;
             Question 4 or Question 5 of the &quot;Since Last Visit&quot; version of the Columbia Suicide&#xD;
             Severity Rating Scale (CSSRS) at the Day 1 Visit. However, participants will not be&#xD;
             excluded if, based upon a mental healthcare professional assessment, and the&#xD;
             investigator's judgment of benefit/risk, the participant is deemed suitable for&#xD;
             receiving study medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Cares</last_name>
    <role>Study Director</role>
    <affiliation>001 844 599 2273 (UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Psp002 40122</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psp002 40002</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>40277 Psp002</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psp002 40276</name>
      <address>
        <city>DÃ¼sseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psp002 40278</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psp002 40024</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psp002 40267</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psp002 40100</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psp002 40268</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>40175 Psp002</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psp002 40165</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 1, 2020</study_first_submitted>
  <study_first_submitted_qc>December 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2020</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Progressive supranuclear palsy</keyword>
  <keyword>UCB0107</keyword>
  <keyword>Phase 1B study</keyword>
  <keyword>PSP</keyword>
  <keyword>Bepranemab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paralysis</mesh_term>
    <mesh_term>Supranuclear Palsy, Progressive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Due to the small sample size in this trial, Individual Patient Data cannot be adequately anonymized and there is a reasonable likelihood that individual participants could be re-identified. For this reason, data from this trial cannot be shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

